ValuEngine cut shares of TG Therapeutics (NASDAQ:TGTX) from a hold rating to a sell rating in a research report released on Wednesday morning.
Several other research analysts also recently issued reports on TGTX. BidaskClub downgraded TG Therapeutics from a hold rating to a sell rating in a research report on Tuesday, June 12th. Zacks Investment Research upgraded TG Therapeutics from a sell rating to a hold rating in a research report on Thursday, July 26th. HC Wainwright restated a buy rating and set a $38.00 price objective on shares of TG Therapeutics in a research report on Tuesday, August 7th. Finally, Raymond James downgraded TG Therapeutics from a strong-buy rating to an outperform rating and cut their price objective for the stock from $22.00 to $12.00 in a research report on Tuesday. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of Hold and an average price target of $26.40.
Shares of TG Therapeutics stock opened at $5.25 on Wednesday. TG Therapeutics has a 1 year low of $4.95 and a 1 year high of $17.35. The company has a market cap of $426.52 million, a P/E ratio of -2.75 and a beta of 1.16.
In other TG Therapeutics news, CFO Sean A. Power sold 47,191 shares of the business’s stock in a transaction on Tuesday, July 3rd. The stock was sold at an average price of $13.21, for a total value of $623,393.11. Following the completion of the transaction, the chief financial officer now directly owns 473,267 shares in the company, valued at approximately $6,251,857.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 15.10% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of TGTX. Xact Kapitalforvaltning AB acquired a new position in TG Therapeutics in the 2nd quarter valued at $139,000. Quantitative Systematic Strategies LLC acquired a new position in TG Therapeutics in the 2nd quarter valued at $146,000. Cubist Systematic Strategies LLC acquired a new position in TG Therapeutics in the 1st quarter valued at $176,000. Birchview Capital LP acquired a new position in TG Therapeutics in the 2nd quarter valued at $197,000. Finally, North Star Investment Management Corp. acquired a new stake in shares of TG Therapeutics during the 2nd quarter worth $276,000. Institutional investors own 48.99% of the company’s stock.
About TG Therapeutics
TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.
Featured Article: How to Invest in Growth Stocks
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.